Video Experimental Relacionado
Updated: Jan 18, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
Obesidad: Novedades en 2025
Farah-Noor Boudjaoui1,2, Lucie Favre1,2, Sara Santini1,2
1Centre d'obésité, Centre hospitalier universitaire vaudois, Rue Saint-Martin 3, 1003 Lausanne.
Revue medicale suisse
|January 16, 2026
Resumen
La obesidad causa millones de muertes al año, pero pocos sistemas de salud están preparados. Las nuevas terapias basadas en incretinas están revolucionando el tratamiento de la obesidad, con muchos ensayos clínicos en curso.
Área de la Ciencia:
- Salud Pública
- Endocrinología
- Farmacología
Sus antecedentes:
- La obesidad y el sobrepeso contribuyen a 1,6 millones de muertes prematuras al año.
- Se estima que el impacto económico mundial de la obesidad es de 3 billones de dólares al año.
- Los sistemas de salud actuales están insuficientemente preparados para gestionar la crisis de la obesidad, y solo el 7% de los países muestran preparación.
Objetivo del estudio:
- Destacar los avances recientes en el tratamiento de la obesidad.
- Analizar las estrategias terapéuticas emergentes para la obesidad.
- Explorar las perspectivas futuras en la farmacoterapia de la obesidad.
Principales métodos:
- Revisión de la literatura actual sobre el manejo de la obesidad.
- Análisis de los ensayos clínicos en curso para tratamientos de la obesidad.
- Enfoque en la evolución de las intervenciones farmacológicas, en particular las terapias basadas en incretinas.
Principales resultados:
- Se está produciendo un cambio significativo en la prestación de la atención de la obesidad, que redefine su diagnóstico, fisiopatología y complicaciones.
- El tratamiento farmacológico de la obesidad está evolucionando rápidamente.
- Hay más de 1000 ensayos clínicos en curso, la mayoría en las fases II y III, lo que indica una intensa actividad investigadora.
Conclusiones:
- Las terapias basadas en incretinas son un importante motor de los avances actuales en la farmacoterapia de la obesidad.
- El campo está preparado para avances terapéuticos significativos en el manejo de la obesidad.
- La investigación continua y los ensayos clínicos son esenciales para abordar la epidemia mundial de obesidad.
Videos de Conceptos Relacionados
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
01:21Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
01:30Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
01:19Energy Balance
1.2K
The human body gets energy from the three macronutrients: carbohydrates, proteins, and fats. Energy is released when the chemical bonds in the organic compounds present in the food are broken down. The energy content of food is measured in kilocalories (kcal), defined as the amount of heat required to raise the temperature of one kilogram of water by one degree Celsius. This value is determined by measuring the temperature change of the water surrounding a calorimeter after the complete...
1.2K